Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Jasper Therapeutics, Inc. - Class A Common Stock (NQ:JSPR)

1.750 +0.030 (+1.74%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 592,535
Open 1.750
Bid (Size) 1.710 (100)
Ask (Size) 2.030 (200)
Prev. Close 1.720
Today's Range 1.710 - 1.800
52wk Range 1.560 - 26.05
Shares Outstanding 736,213
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Driven Brands and Jasper Therapeutics on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Jasper Therapeutics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit

Performance

YTD
-91.7%
-91.7%
1 Month
-24.9%
-24.9%
3 Month
-40.1%
-40.1%
6 Month
-63.3%
-63.3%
1 Year
-92.3%
-92.3%

More News

Read More
News headline image
JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Jasper Therapeutics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Via TheNewswire.com
Topics Lawsuit
News headline image
JSPR FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Announces that Jasper Therapeutics Investors Have Opportunity to Lead Class Action Lawsuit
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
Bragar Eagel & Squire, P.C. Reminds Stockholders of Jasper, KBR, Spirit, and Molina of the Upcoming Deadlines and Urges Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Deadline Soon: Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
JSPR DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Jasper Therapeutics, Inc. Investors to Secure Counsel Before Important November 18 Deadline in Securities Class Action – JSPR
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Jasper Therapeutics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Via NewMediaWire
Topics Lawsuit
News headline image
JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Jasper Therapeutics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Via TheNewswire.com
Topics Lawsuit
News headline image
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
CoreWeave Bulls Should Brace For 'Wild, Lumpy, Volatile Ride,' JPMorgan Says ↗
Via Benzinga
Topics Artificial Intelligence
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors of Jasper, KBR, Spirit, and Molina to Contact the Firm About their Rights
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Jasper Therapeutics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Via TheNewswire.com
Topics Lawsuit
News headline image
JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Jasper Therapeutics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Via NewMediaWire
Topics Lawsuit
News headline image
JSPR SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Announces that Jasper Therapeutics Investors Have Opportunity to Lead Class Action Lawsuit
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
JSPR Deadline: Rosen Law Firm Urges Jasper Therapeutics, Inc. (NASDAQ: JSPR) Stockholders to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Jasper Therapeutics
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
JSPR DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Jasper Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – JSPR
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
JSPR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
JASPER CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Reminds Jasper Stockholders of the November 18th Deadline for Filed Class Action
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Jasper Therapeutics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Via NewMediaWire
Topics Lawsuit
News headline image
JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Jasper Therapeutics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Via TheNewswire.com
Topics Lawsuit

Frequently Asked Questions

Is Jasper Therapeutics, Inc. - Class A Common Stock publicly traded?
Yes, Jasper Therapeutics, Inc. - Class A Common Stock is publicly traded.
What exchange does Jasper Therapeutics, Inc. - Class A Common Stock trade on?
Jasper Therapeutics, Inc. - Class A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Jasper Therapeutics, Inc. - Class A Common Stock?
The ticker symbol for Jasper Therapeutics, Inc. - Class A Common Stock is JSPR on the Nasdaq Stock Market
What is the current price of Jasper Therapeutics, Inc. - Class A Common Stock?
The current price of Jasper Therapeutics, Inc. - Class A Common Stock is 1.750
When was Jasper Therapeutics, Inc. - Class A Common Stock last traded?
The last trade of Jasper Therapeutics, Inc. - Class A Common Stock was at 11/25/25 04:00 PM ET
What is the market capitalization of Jasper Therapeutics, Inc. - Class A Common Stock?
The market capitalization of Jasper Therapeutics, Inc. - Class A Common Stock is 1.29M
How many shares of Jasper Therapeutics, Inc. - Class A Common Stock are outstanding?
Jasper Therapeutics, Inc. - Class A Common Stock has 1M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.